+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Dyslipidemia Drugs Market by Drug Class, By Indication, by Distribution Channel, and By Region

  • PDF Icon

    Report

  • 200 Pages
  • March 2024
  • Region: Global
  • Erevna Healthcare
  • ID: 5941919
The global dyslipidemia drugs market size was estimated to be USD 18.29 billion in 2023 and is expected to reach USD 30.98 billion by 2034 with a CAGR of 4.91% during the forecast period 2024-2034. Rising prevalence of dyslipidemia, growing cardiovascular disease burden, increasing awareness and screening, advancements in drug development, government initiatives for cardiovascular health, and expanding geriatric population will drive the market growth,

Millions of people worldwide suffer from dyslipidemia, which is defined by elevated levels of triglycerides and cholesterol. According to WHO estimates, one in three persons have high levels of low-density lipoprotein (LDL, or "bad") cholesterol. One of the main risk factors for cardiovascular diseases (CVDs), the world's leading cause of mortality, is dyslipidemia. This correlation greatly increases the demand for efficient cholesterol-lowering drugs. For instance, in December 2023, Pfizer Inc. introduced Inclusa (inclisiran), the first siRNA treatment for decreasing cholesterol.

By drug class, the statins segment accounted for the highest revenue-grossing segment in the global dyslipidemia drugs market in 2023 owing to the well-established efficacy and widespread utilization of statin medications, their proven ability to lower cholesterol levels and reduce cardiovascular risk, consistent physician preference, and continuous patient adoption, supported by a robust body of clinical evidence endorsing their effectiveness in managing dyslipidemia. For instance, in September 2023, AstraZeneca plc presented encouraging Phase 3 findings from the MEDSCAPE-2B trial, which used Solibris (bimekizumab) to treat mixed dyslipidemia and ASCVD. Additionally, the PCSK9 inhibitors segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of their potent cholesterol-lowering capabilities, the demand for novel and targeted approaches in dyslipidemia management, advancements in biopharmaceutical technology facilitating the development of these innovative drugs, and a growing patient population seeking alternative therapeutic options for better lipid control and cardiovascular risk reduction.

By indication, the hypercholesterolemia segment accounted for the highest revenue-grossing segment in the global dyslipidemia drugs market in 2023 owing to the prevalence of elevated cholesterol levels worldwide, the increasing awareness and diagnosis of hypercholesterolemia as a significant cardiovascular risk factor, a growing patient pool seeking pharmacological interventions, and the widespread prescription of lipid-lowering medications. For instance, in December 2023, the primary goal of Amgen Inc.'s Phase 3 HARMONY trial for familial chylomicronemia syndrome with AMG 890 was fulfilled. Additionally, the mixed dyslipidemia segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing recognition of its complex nature involving elevated levels of both cholesterol and triglycerides, an increased focus on comprehensive lipid management strategies, advancements in drug development targeting mixed dyslipidemia specifically, and rising patient demand for tailored therapeutic interventions addressing the multifaceted aspects of lipid disorders for improved cardiovascular risk reduction.

By distribution channel, the retail pharmacies segment accounted for the highest revenue-grossing segment in the global dyslipidemia drugs market in 2023 owing to the widespread accessibility and convenience offered by retail outlets, the increasing trend of self-management and prescription fulfillment at community pharmacies, and a growing patient preference for obtaining dyslipidemia medications through easily accessible retail channels, fostering better adherence and continuity of care. For instance, in December 2023, Eli Lilly and Company announced a partnership with Bayer to research and market novel treatments for cardiovascular disorders, including dyslipidemia. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the escalating adoption of e-commerce and digital healthcare platforms, increased consumer convenience in procuring medications from the comfort of their homes, the growing trend of telemedicine, and advancements in secure online transactions and prescription verification, facilitating a shift towards the digital distribution of dyslipidemia drugs.

North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, a high prevalence of dyslipidemia in the population, strong emphasis on cardiovascular health, extensive research and development activities, widespread adoption of advanced medical technologies, and robust healthcare policies, which collectively contribute to a significant demand for dyslipidemia drugs in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness of dyslipidemia and cardiovascular health, rising incidence of lifestyle-related risk factors, expanding healthcare infrastructure, growing healthcare expenditures, and a burgeoning population with changing dietary habits and sedentary lifestyles, all of which contribute to a heightened demand for dyslipidemia drugs in the region. For instance, in June 2023, the Bristol Myers Squibb Company and Akcea Therapeutics entered into a commercial agreement for the commercialization of VOLTADOL (colesevelam acetate) for the treatment of familial hypercholesterolemia.

This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.

Report Scope:

  • Base Year: 2023
  • Forecast Period: 2024-2034
  • Study Coverage
  • Market Forecast by Drug Class, Indication, and Distribution Channel
  • Market Forecast for 5 Regions and 17+ Countries
  • North America (U.S. and Canada)
  • Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
  • Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
  • Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
  • MEA (South Africa, GCC, Rest of MEA)
  • Exhaustive Company Profiles of the Top 10+ Major Market Players
  • 20% Free Customization Available to Meet Your Exact Requirement.

Segmentation: Dyslipidemia Drugs Market Report 2023 - 2034

Dyslipidemia Drugs Market Analysis & Forecast by Drug Class 2023 - 2034 (Revenue USD Bn)

  • Statins
  • Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors
  • Bile Acid Sequestrants
  • Fibric Acid Derivatives
  • Niacin
  • Others

Dyslipidemia Drugs Market Analysis & Forecast by Indication 2023 - 2034 (Revenue USD Bn)

  • Hypercholesterolemia
  • Mixed Dyslipidemia
  • Hypertriglyceridemia
  • Others

Dyslipidemia Drugs Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)

  • Hospital Pharmacy
  • Retail pharmacy
  • Online Pharmacy

Dyslipidemia Drugs Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
  • Middle East & Africa
  • South Africa
  • GCC
  • Rest of MEA

Table of Contents

1. Research Methodology
1.1. Study Objectives
1.2. Study Scope
1.3. Research Assumptions
1.4. Research Framework
2. Introduction
2.1. Market Definition
2.2. Global Dyslipidemia Drugs Market Overview
3. Executive Summary
4. Market Environment Analysis
4.1. Porter’s 5 Forces Analysis
4.2. PESTEL Analysis
4.3. SWOT Analysis
5. Market Dynamics
5.1. Drivers Analysis
5.2. Restraints Analysis
5.3. Opportunities Analysis
5.4. Threats Analysis
5.5. Trend Analysis
6. COVID-19 Impact Analysis
7. Dyslipidemia Drugs Market: Drug Class Estimates & Trend Analysis
7.1. Drug Class Segment Opportunity Analysis
7.2. Statins
7.2.1. Statins Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.3. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors
7.3.1. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.4. Bile Acid Sequestrants
7.4.1. Bile Acid Sequestrants Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.5. Fibric Acid Derivatives
7.5.1. Fibric Acid Derivatives Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.6. Niacin
7.6.1. Niacin Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
7.7. Others
7.7.1. Others Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
8. Dyslipidemia Drugs Market: Indication Estimates & Trend Analysis
8.1. Indication Segment Opportunity Analysis
8.2. Hypercholesterolemia
8.2.1. Hypercholesterolemia Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
8.3. Mixed Dyslipidemia
8.3.1. Mixed Dyslipidemia Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
8.4. Hypertriglyceridemia
8.4.1. Hypertriglyceridemia Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
8.5. Others
8.5.1. Others Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
9. Dyslipidemia Drugs Market: Distribution Channel Estimates & Trend Analysis
9.1. Distribution Channel Segment Opportunity Analysis
9.2. Hospital Pharmacy
9.2.1. Hospital Pharmacy Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
9.3. Retail pharmacy
9.3.1. Retail Pharmacy Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
9.4. Online Pharmacy
9.4.1. Online Pharmacy Market Analysis & Forecast, 2023-2034 (Revenue, USD Bn)
10. Regional Market Analysis
10.1. Regional Market Opportunity Analysis
11. North America Dyslipidemia Drugs Market
11.1. North America Dyslipidemia Drugs Market
11.1.1. North America Dyslipidemia Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
11.1.2. North America Dyslipidemia Drugs Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
11.1.3. North America Dyslipidemia Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
11.1.4. North America Dyslipidemia Drugs Market Size and Forecast, By Indication, 2023-2034 (Revenue USD Bn)
11.1.5. North America Dyslipidemia Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
11.2. U.S. Global Dyslipidemia Drugs Market
11.2.1. U.S. Dyslipidemia Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
11.2.2. U.S. Dyslipidemia Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
11.2.3. U.S. Dyslipidemia Drugs Market Size and Forecast, By Indication, 2023-2034 (Revenue USD Bn)
11.2.4. U.S. Dyslipidemia Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
11.3. Canada Global Dyslipidemia Drugs Market
11.3.1. Canada Dyslipidemia Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
11.3.2. Canada Dyslipidemia Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
11.3.3. Canada Dyslipidemia Drugs Market Size and Forecast, By Indication, 2023-2034 (Revenue USD Bn)
11.3.4. Canada Dyslipidemia Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
12. Europe Global Dyslipidemia Drugs Market
12.1. Europe Global Dyslipidemia Drugs Market
12.1.1. Europe Dyslipidemia Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.1.2. Europe Dyslipidemia Drugs Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
12.1.3. Europe Dyslipidemia Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
12.1.4. Europe Dyslipidemia Drugs Market Size and Forecast, By Indication, 2023-2034 (Revenue USD Bn)
12.1.5. Europe Dyslipidemia Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
12.2. Germany Global Dyslipidemia Drugs Market
12.2.1. Germany Dyslipidemia Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.2.2. Germany Dyslipidemia Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
12.2.3. Germany Dyslipidemia Drugs Market Size and Forecast, By Indication, 2023-2034 (Revenue USD Bn)
12.2.4. Germany Dyslipidemia Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
12.3. UK Global Dyslipidemia Drugs Market
12.3.1. UK Dyslipidemia Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.3.2. UK Dyslipidemia Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
12.3.3. UK Dyslipidemia Drugs Market Size and Forecast, By Indication, 2023-2034 (Revenue USD Bn)
12.3.4. UK Dyslipidemia Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
12.4. France Global Dyslipidemia Drugs Market
12.4.1. France Dyslipidemia Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.4.2. France Dyslipidemia Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
12.4.3. France Dyslipidemia Drugs Market Size and Forecast, By Indication, 2023-2034 (Revenue USD Bn)
12.4.4. France Dyslipidemia Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
12.5. Spain Global Dyslipidemia Drugs Market
12.5.1. Spain Dyslipidemia Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.5.2. Spain Dyslipidemia Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
12.5.3. Spain Dyslipidemia Drugs Market Size and Forecast, By Indication, 2023-2034 (Revenue USD Bn)
12.5.4. Spain Dyslipidemia Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
12.6. Italy Global Dyslipidemia Drugs Market
12.6.1. Italy Dyslipidemia Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.6.2. Italy Dyslipidemia Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
12.6.3. Italy Dyslipidemia Drugs Market Size and Forecast, By Indication, 2023-2034 (Revenue USD Bn)
12.6.4. Italy Dyslipidemia Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
12.7. Rest of Europe Global Dyslipidemia Drugs Market
12.7.1. Rest of Europe Dyslipidemia Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
12.7.2. Rest of Europe Dyslipidemia Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
12.7.3. Rest of Europe Dyslipidemia Drugs Market Size and Forecast, By Indication, 2023-2034 (Revenue USD Bn)
12.7.4. Rest of Europe Dyslipidemia Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
13. Asia Pacific Global Dyslipidemia Drugs Market
13.1. Asia Pacific Global Dyslipidemia Drugs Market
13.1.1. Asia Pacific Dyslipidemia Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.1.2. Asia Pacific Dyslipidemia Drugs Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
13.1.3. Asia Pacific Dyslipidemia Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
13.1.4. Asia Pacific Dyslipidemia Drugs Market Size and Forecast, By Indication, 2023-2034 (Revenue USD Bn)
13.1.5. Asia Pacific Dyslipidemia Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
13.2. Japan Global Dyslipidemia Drugs Market
13.2.1. Japan Dyslipidemia Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.2.2. Japan Dyslipidemia Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
13.2.3. Japan Dyslipidemia Drugs Market Size and Forecast, By Indication, 2023-2034 (Revenue USD Bn)
13.2.4. Japan Dyslipidemia Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
13.3. China Global Dyslipidemia Drugs Market
13.3.1. China Dyslipidemia Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.3.2. China Dyslipidemia Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
13.3.3. China Dyslipidemia Drugs Market Size and Forecast, By Indication, 2023-2034 (Revenue USD Bn)
13.3.4. China Dyslipidemia Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
13.4. India Global Dyslipidemia Drugs Market
13.4.1. India Dyslipidemia Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.4.2. India Dyslipidemia Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
13.4.3. India Dyslipidemia Drugs Market Size and Forecast, By Indication, 2023-2034 (Revenue USD Bn)
13.4.4. India Dyslipidemia Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
13.5. South Korea Global Dyslipidemia Drugs Market
13.5.1. South Korea Dyslipidemia Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.5.2. South Korea Dyslipidemia Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
13.5.3. South Korea Dyslipidemia Drugs Market Size and Forecast, By Indication, 2023-2034 (Revenue USD Bn)
13.5.4. South Korea Dyslipidemia Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
13.6. Australia Global Dyslipidemia Drugs Market
13.6.1. Australia Dyslipidemia Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.6.2. Australia Dyslipidemia Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
13.6.3. Australia Dyslipidemia Drugs Market Size and Forecast, By Indication, 2023-2034 (Revenue USD Bn)
13.6.4. Australia Dyslipidemia Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
13.7. Rest of Asia Pacific Global Dyslipidemia Drugs Market
13.7.1. Rest of Asia Pacific Dyslipidemia Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
13.7.2. Rest of Asia Pacific Dyslipidemia Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
13.7.3. Rest of Asia Pacific Dyslipidemia Drugs Market Size and Forecast, By Indication, 2023-2034 (Revenue USD Bn)
13.7.4. Rest of Asia Pacific Dyslipidemia Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
14. Latin America Global Dyslipidemia Drugs Market
14.1. Latin America Global Dyslipidemia Drugs Market
14.1.1. Latin America Dyslipidemia Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.1.2. Latin America Dyslipidemia Drugs Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
14.1.3. Latin America Dyslipidemia Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
14.1.4. Latin America Dyslipidemia Drugs Market Size and Forecast, By Indication, 2023-2034 (Revenue USD Bn)
14.1.5. Latin America Dyslipidemia Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
14.2. Brazil Global Dyslipidemia Drugs Market
14.2.1. Brazil Dyslipidemia Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.2.2. Brazil Dyslipidemia Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
14.2.3. Brazil Dyslipidemia Drugs Market Size and Forecast, By Indication, 2023-2034 (Revenue USD Bn)
14.2.4. Brazil Dyslipidemia Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
14.3. Mexico Global Dyslipidemia Drugs Market
14.3.1. Mexico Dyslipidemia Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.3.2. Mexico Dyslipidemia Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
14.3.3. Mexico Dyslipidemia Drugs Market Size and Forecast, By Indication, 2023-2034 (Revenue USD Bn)
14.3.4. Mexico Dyslipidemia Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
14.4. Argentina Global Dyslipidemia Drugs Market
14.4.1. Argentina Dyslipidemia Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.4.2. Argentina Dyslipidemia Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
14.4.3. Argentina Dyslipidemia Drugs Market Size and Forecast, By Indication, 2023-2034 (Revenue USD Bn)
14.4.4. Argentina Dyslipidemia Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
14.5. Rest of Latin America Global Dyslipidemia Drugs Market
14.5.1. Rest of Latin America Dyslipidemia Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
14.5.2. Rest of Latin America Dyslipidemia Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
14.5.3. Rest of Latin America Dyslipidemia Drugs Market Size and Forecast, By Indication, 2023-2034 (Revenue USD Bn)
14.5.4. Rest of Latin America Dyslipidemia Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
15. MEA Global Dyslipidemia Drugs Market
15.1. MEA Global Dyslipidemia Drugs Market
15.1.1. MEA Dyslipidemia Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
15.1.2. MEA Dyslipidemia Drugs Market Size and Forecast, By Country, 2023-2034 (Revenue USD Bn)
15.1.3. MEA Dyslipidemia Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
15.1.4. MEA Dyslipidemia Drugs Market Size and Forecast, By Indication, 2023-2034 (Revenue USD Bn)
15.1.5. MEA Dyslipidemia Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
15.2. GCC Global Dyslipidemia Drugs Market
15.2.1. GCC Dyslipidemia Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
15.2.2. GCC Dyslipidemia Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
15.2.3. GCC Dyslipidemia Drugs Market Size and Forecast, By Indication, 2023-2034 (Revenue USD Bn)
15.2.4. GCC Dyslipidemia Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
15.3. South Africa Global Dyslipidemia Drugs Market
15.3.1. South Africa Dyslipidemia Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
15.3.2. South Africa Dyslipidemia Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
15.3.3. South Africa Dyslipidemia Drugs Market Size and Forecast, By Indication, 2023-2034 (Revenue USD Bn)
15.3.4. South Africa Dyslipidemia Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
15.4. Rest of MEA Global Dyslipidemia Drugs Market
15.4.1. Rest of MEA Dyslipidemia Drugs Market Size and Forecast, 2023-2034 (Revenue USD Bn)
15.4.2. Rest of MEA Dyslipidemia Drugs Market Size and Forecast, By Drug Class, 2023-2034 (Revenue USD Bn)
15.4.3. Rest of MEA Dyslipidemia Drugs Market Size and Forecast, By Indication, 2023-2034 (Revenue USD Bn)
15.4.4. Rest of MEA Dyslipidemia Drugs Market Size and Forecast, By Distribution Channel, 2023-2034 (Revenue USD Bn)
16. Competitor Analysis
16.1. Company Market Share Analysis, 2023
16.2. Major Recent Developments
17. Company Profiles
17.1. Pfizer Inc.
17.2. AstraZeneca plc
17.3. Merck & Co., Inc.
17.4. Novartis AG
17.5. Amgen Inc.
17.6. Sanofi
17.7. Eli Lilly and Company
17.8. Bristol Myers Squibb Company
17.9. AbbVie Inc.
17.10. GlaxoSmithKline plc
17.11. Daiichi Sankyo Company, Limited
17.12. Regeneron Pharmaceuticals, Inc.
17.13. Mylan N.V. (now Viatris Inc.)
17.14. Johnson & Johnson
17.15. Takeda Pharmaceutical Company Limited
18. Conclusion19. Recommendations

Companies Mentioned

  • Sanofi
  • Eli Lilly and Company
  • Bristol Myers Squibb Company
  • AbbVie Inc.
  • GlaxoSmithKline plc
  • Daiichi Sankyo Company
  • Limited
  • Regeneron Pharmaceuticals Inc.
  • Mylan N.V. (now Viatris Inc.)
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Limited

Table Information